Overview of recently reported trial results incorporating BV or CPIs for patients after ≥1 line of salvage treatment
| Study . | N . | Intervention . | CMR . | ORR . | PFS . | OS . |
|---|---|---|---|---|---|---|
| Chen et al (2016)17 | 102 | BV | 34% | 75% | 5 years: 22% | 5 years: 41% |
| O'Connor et al (2018)29 | 65 | BV + bendamustine | 32% | 71% | 2 years: 50%* | 2 years: 65%* |
| Armand et al (2018)18 | 243 | Nivolumab | 16% | 69% | 1 year: 50%* | 1 year: 92% |
| Chen et al (2019)2 | 210 | Pembrolizumab | 27.6% | 71.9% | 2 years: 31.3% | 2 years: 90.9% |
| Shi et al (2019)30 | 92 | Sintilimab | 34% | 80.4% | 6 month: 77.6% | 6 month: 100% |
| Song et al (2019)31 | 75 | Camrelizumab | 28% | 76% | 9 month: 76.6% | 9 month: 96%* |
| Armand et al (2020)32 | 31 | Pembrolizumab | 19% | 58% | 2 years: 30% | 2 years: 87% |
| Song et al (2020)33 | 70 | Tislelizumab | 63.9% | 87.1% | 9 month: 74.5% | 9 month: 98.6% |
| Diefenbach et al (2020)34 (including n = 26 first relapse) | 64 | Ipilimumab + BV vs nivolumab + BV vs ipilimumab + nivolumab + BV | 60%/65%/84% | 80%/94%/95% | 1 year: 59%/77%/87% | 1 year: 90%*/80%*/95%*/ |
| Kuruvilla et al (2021)35 | 304 | Pembrolizumab (n = 151) vs BV (n = 152) | 25% vs 24% | 66% vs 54% | 2 years: 35% vs 25% | — |
| Liu et al (2021)36 | 61 | Camrelizumab monotherapy vs camrelizumab + decitabine | 79% vs 32% for camrelizumab + decitabine vs camrelizumab | 95% vs 89% | 2 years: 67% vs 42% | 2 years: 100% |
| Study . | N . | Intervention . | CMR . | ORR . | PFS . | OS . |
|---|---|---|---|---|---|---|
| Chen et al (2016)17 | 102 | BV | 34% | 75% | 5 years: 22% | 5 years: 41% |
| O'Connor et al (2018)29 | 65 | BV + bendamustine | 32% | 71% | 2 years: 50%* | 2 years: 65%* |
| Armand et al (2018)18 | 243 | Nivolumab | 16% | 69% | 1 year: 50%* | 1 year: 92% |
| Chen et al (2019)2 | 210 | Pembrolizumab | 27.6% | 71.9% | 2 years: 31.3% | 2 years: 90.9% |
| Shi et al (2019)30 | 92 | Sintilimab | 34% | 80.4% | 6 month: 77.6% | 6 month: 100% |
| Song et al (2019)31 | 75 | Camrelizumab | 28% | 76% | 9 month: 76.6% | 9 month: 96%* |
| Armand et al (2020)32 | 31 | Pembrolizumab | 19% | 58% | 2 years: 30% | 2 years: 87% |
| Song et al (2020)33 | 70 | Tislelizumab | 63.9% | 87.1% | 9 month: 74.5% | 9 month: 98.6% |
| Diefenbach et al (2020)34 (including n = 26 first relapse) | 64 | Ipilimumab + BV vs nivolumab + BV vs ipilimumab + nivolumab + BV | 60%/65%/84% | 80%/94%/95% | 1 year: 59%/77%/87% | 1 year: 90%*/80%*/95%*/ |
| Kuruvilla et al (2021)35 | 304 | Pembrolizumab (n = 151) vs BV (n = 152) | 25% vs 24% | 66% vs 54% | 2 years: 35% vs 25% | — |
| Liu et al (2021)36 | 61 | Camrelizumab monotherapy vs camrelizumab + decitabine | 79% vs 32% for camrelizumab + decitabine vs camrelizumab | 95% vs 89% | 2 years: 67% vs 42% | 2 years: 100% |
Data have been extracted from available Kaplan-Meier curves using WebPlot Digitizer.